

# بسم الله الرحمن الرحيم





# شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم





# جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

## قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



## يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار





# بعض الوثائق الأصلية تالفة







بالرسالة صفحات  
لم ترد بالأصل



BIN. 20

# EPIDEMIOLOGICAL FEATURES OF PULMONARY TUBERCULOSIS AND COST- EFFECTIVENESS OF DIRECTLY OBSERVED TREATMENT, SHORT-COURSE (DOTS).

## ***Thesis***

*Submitted for Partial Fulfilment of the Requirements For  
M.D Degree of Community & Environmental Medicine.*

***By***

***Mohamed Ahmed Gaafar***

(M.B., B.Ch., M.Sc.)

***Supervised by:***

 ***Prof. Dr. Taghreed M. Farahat***

Prof. & Head of Community, Environmental  
& Occupational Medicine.  
Faculty of Medicine, Menoufiya University.

***Prof. Dr. Mohamed K. El-sobky***

Prof. of Community, Environmental &  
Occupational Medicine.  
Faculty of Medicine, Menoufiya University.

***Dr. Rabie D. El-bahnasy***

Ass. Prof. of Community, Environmental &  
Occupational Medicine.  
Faculty of Medicine, Menoufiya University.

***Dr. Omayma A. Mohamed***

Lecturer of Community, Environmental &  
Occupational Medicine.  
Faculty of Medicine, Menoufiya University.

***Dr. Afaf Osman Helmy***

Dean of Embaba Technical Health Institute.

***Faculty of Medicine  
Menoufiya University***

2002







﴿سورة الأعراف الآية ٨٩﴾

## لجنة الحكم والمناقشة

التوقيع

الاسم

- .....  
.....  
.....  
.....  
.....  
.....
- د. / تغريد محمد فرحات  
أستاذ ورئيس قسم طب المجتمع والبيئة وطب الصناعات - طب المنوفية  
د. / محمد كامل السبكي  
أستاذ بقسم طب المجتمع والبيئة وطب الصناعات - طب المنوفية  
د. / جعفر محمد عبد الرسول  
أستاذ بقسم طب المجتمع والبيئة وطب الصناعات - طب المنوفية  
د. / عادل عبد الغفار السيد  
أستاذ ورئيس قسم طب المجتمع والبيئة وطب الصناعات - طب المنصورة





## ACKNOWLEDGMENT

First and for most, I feel indebted to **ALAAH** the most kind and the most merciful.

I would like to express my deepest gratitude and thanks to **Prof. Dr. Taghreed M. Farahat**, Prof. & Head of Community, Environmental & Occupational Medicine, Menoufiya University, for her valuable advice, sincere help, continuous encouragement and precious guidance.

My deepest gratitude and appreciation to **Prof. Dr. Mohamed K. El-sobky**, Prof. of Community, Environmental & Occupational Medicine, Menoufiya University, for his sincere guidance, valuable suggestions and supervision. His valuable assistance will remain a valid memory.

My profound thanks and deepest gratitude to **Dr. Rabie D. El-bahnasy**, Assistant Prof. of Community, Environmental & Occupational Medicine, Menoufiya University, for his valuable instructions, supervisions, fruitful assistance, generosity in time and efforts.

I wish to acknowledge, the enormous and keen assistance of **Dr. Omayma A. Mohamed**, Lecturer of Community, Environmental & Occupational Medicine, Menoufiya University, for her sincere guidance, valuable suggestions and kind approval to register & supervise this work.

My special deepest thanks and great independence to **Dr. Afaf Osman Helmy**, Dean of Embaba Technical Health Institute, for her unlimited help and kindness, that enabled me to accomplish this work.

I wish to express my profound thanks to **Dr. Atef Awad**, for his keen, valuable, unlimited help and generosity in time and efforts.

Last but not least, my best thanks to all patients, who responded to my questionnaire and supplied me with the needed data & all workers in Menouf and Banha chest hospitals for their unlimited help.

# CONTENTS

	<i>Page</i>
● Introduction	1
● Aims of the work	4
● Review of literature:	
-Magnitude of the problem.	5
-Risk factors	11
-Resurging of tuberculosis.	26
-Diagnosis of pulmonary tuberculosis	32
-Preventive plan for tuberculosis.	45
-Control measures.	47
-Vaccine strategies	50
-Management of tuberculosis.	53
-Directly Observed Treatment, Short course (DOTS).	58
-Economic burden of health care.	67
-Key economic terms and concepts.	72
-Economic evaluation of health care.	81
● Subjects & methods	96
● Results	108
● Discussion	142
● Recommendations	160
● Summary & conclusion	163
● References	167
● Appendices	192
● Arabic Summary	



# LIST OF TABLES

## **Tables in Review:**

	<i>Page</i>
<b>Table (1):</b> Groups at high risk for TB	11
<b>Table (2):</b> Diagnostic difficulties.	32
<b>Table (3):</b> Criteria for activity in pulmonary TB.	35
<b>Table (4):</b> Anti-TB treatment regimens.	54
<b>Table (5):</b> Monitoring of treatment.	55
<b>Table (6):</b> Outcome of treatment.	56
<b>Table (7):</b> How a Non-DOTS approach to TB differs from DOTS?	64
<b>Table (8):</b> Methods of economic evaluation. All relevant costs are measured in monetary terms.	83
<b>Table (9):</b> Standardized life expectancy by age and gender.	93
<b>Table (10):</b> Disability classes and disability weights used in global burden of disease calculations.	94

## **Tables in Subject & Methods:**

<b>Table (1):</b> Activities to be costed by facility.	103
<b>Table (2):</b> Expected life years.	104
<b>Table (3):</b> Patient's cost items.	105

### **Tables in Results:**

<b>Table (1):</b> Trends of pulmonary tuberculosis in Egypt, during the period from January 1991 through December 2000, as reported by NTCP & CAPMAS.	108
<b>Table (2):</b> Distribution of the studied pulmonary tuberculous patients according to sputum smear by: Hospital & Year.	109
<b>Table (3):</b> Age & Sex distribution of the studied pulmonary tuberculous patients, compared to the last national figure (NTCP, year 2000).	110
<b>Table (4):</b> Distribution of the studied pulmonary tuberculous patients & controls by: Residence & Marital status.	111
<b>Table (5):</b> Socio-economic scoring of the studied pulmonary tuberculous patients & controls.	112
<b>Table (6):</b> Number & Percent distribution of the studied pulmonary tuberculous patients & controls by: Ventilation & Sunlight at homes.	115
<b>Table (7):</b> Past history of contact with active tuberculous patient & marker of BCG vaccination among patients & controls.	116
<b>Table (8):</b> Relapse among studied patients according to age.	117
<b>Table (9):</b> Frequencies of other medical illnesses among tuberculous patients & controls.	119
<b>Table (10):</b> Smoking & drug addition among tuberculous patients & controls.	120



<b>Table (11):</b> Type, duration & frequency of smoking among patients & controls	122
<b>Table (12):</b> Risky occupations (for more than 5 years) among patients & controls.	124
<b>Table (13):</b> Evaluation of hospital performance towards the studied pulmonary tuberculous patients.	125
<b>Table (14)</b> Evaluation of hospital performance towards contacts of index cases.	128
<b>Table (15):</b> Average diagnostic health service costs.	129
<b>Table (16):</b> Average health service treatment costs.	130
<b>Table (17):</b> Average incremental costs per PHC visit.	131
<b>Table (18):</b> Average patient costs in DOTS and Non-DOTS.	132
<b>Table (19):</b> Cure (success) rates.	133
<b>Table (20):</b> Average costs per patient and per patient successfully treated (DOTS – PHC).	134
<b>Table (21):</b> Average costs per patient and per patient cured (Non-DOTS, chest hospital)	136

# LIST OF FIGURES

## **Figures in Review:**

	<i>Page</i>
<b>Fig. (1):</b> Approaches for cost estimation.	69
<b>Fig. (2):</b> Theoretical relationship between average and marginal costs in short-run	75
<b>Fig. (3):</b> Theoretical relationship between average and marginal costs in long-run	75
<b>Fig. (4):</b> A framework for thinking about the costs of TB services.	76
<b>Fig. (5):</b> Three dimensions of clinical economics	81

## **Figures in Results:**

<b>Fig. (1):</b> Annual case – detection rate of pulmonary tuberculosis in Egypt, during the period from January 1991 through December 2000, as reported by NTCP & CAPMAS.	137
<b>Fig. (2):</b> Age of the studied pulmonary tuberculous patients compared to the last national figure (NTCP, Egypt 2000).	138
<b>Fig. (3):</b> Relevant medical illness among tuberculous patients & controls.	139
<b>Fig. (4):</b> Cost-breakdown of DOTS through PHC units.	140
<b>Fig. (5):</b> Cost-breakdown of Non-DOTS through. chest hospital.	141



## LIST OF ABBREVIATIONS

ACTG	AIDS Clinical Trials Group.
AIDS	Acquired Immunodeficiency Virus Syndrome.
ATS	American Thoracic Society.
BCG	Bacillus Calmette and Guerin.
BTA	British Tuberculosis Association.
CAPMAS	Central Agency of Public Mobilization & Statistics.
CDC	Center for Disease Control & prevention.
CEA	Cost-Effectiveness Analysis.
CPCRA	Community Programs for Clinical Research on AIDS.
CT	Computerized Tomography.
CUA	Cost-Utility Analysis.
DOTS	Directly Observed Treatment- Short course.
ELISA	Enzyme – Linked Immuno Sorbent Assays.
EPI	Extended Program of Immunization.
HC	Human Capital approach.
HIO	Health Insurance Organization.
HIV	Human Immunodeficiency Virus.
HPLC	High Performance Liquid Chromatography.
INH	Isoniazide.
IU	International Unit.
IUATLD	International Union Against Tuberculosis and Lung Diseases.
MDR	Multi-Drug Resistant.
MOHP	Ministry Of Health and Population.
MTB	Mycobacterium Tuberculosis.
NTCP	National Tuberculosis and Control Program.
OT	Old Tuberculin.
PCR	Polymerase Chain Reaction assays.
PHC	Primary Health Care.
PPD	Purified Protein Derivative.
QALYs	Quality Adjusted Life Years.
RIA	Radio Immuno Assays.
SLE	Systemic Lupus Erythematosus.
TB	Tubercle Bacilli.
TPFS	Tuberculous Patient's Friendship Society.
TST	Tuberculin Skin Test.
UK	United Kingdom.
USA	United States of America.
WHO	World Health Organization.
WTP	Willingness To Pay approach.